The Top Biopharma Pharma Stories of 2004
Windhover's pick of the top pharma/ biotech stories of 2004 range from the firestorm over Vioxx and Celebrex, the problem of the blockbuster pharma model, the biogenerics that weren't, the pricing squeeze on drugs; greater scrutiny of clinical data from a beleaguered, gun-shy FDA; new uses of existing molecules, which "jump-started" companies looking for financing; the tail-end of Big Pharma consolidation; and the rise of oncology.
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.